Acumen Pharmaceuticals

Cash flows are entirely dependent on a late‑2026 Phase 2 readout, creating a binary path. No recurring revenue exists, and success would still require an additional pivotal program and regulatory reviews before potential commercialization.

Even with success, adoption depends on diagnostic capacity, MRI monitoring logistics, center of excellence throughput, and payer implementation details that have complicated earlier rollouts. This profile is inconsistent with our preference for steady, compounding toll‑booth businesses.